{"product_id":"alnylam-marketing-mix","title":"Alnylam Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Alnylam’s product innovation, pricing strategy, distribution channels, and targeted promotion combine to drive competitive advantage in RNAi therapeutics—this concise preview highlights key strategic moves and market signals. Unlock the full 4Ps Marketing Mix Analysis for granular data, editable slides, and actionable recommendations to use in pitches, reports, or strategic planning. Purchase the complete report to save hours and apply a ready-made, expert-backed framework to your work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial RNAi Therapeutic Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam’s commercial RNAi therapeutic portfolio includes five marketed products: Amvuttra, Onpattro, Givlaari, Oxlumo, and Leqvio (partnered with Novartis), generating combined 2024 revenue of about $3.2B and company-wide 2025 guidance near $3.6B. These RNAi drugs silence mRNA to stop disease proteins, targeting rare genetic disorders like hATTR and acute hepatic porphyria and common metabolic disease (LDL-C) via Leqvio. By late 2025 patient migration to Amvuttra made it the market leader in hATTR, capturing roughly 65–70% share and driving Amvuttra yearly net product sales to an estimated $900–950M. The Leqvio partnership contributed materially: Novartis-reported 2025 net sales exceeding $1.1B through global launches and primary care uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Delivery Platform Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam uses proprietary GalNAc-conjugate and lipid nanoparticle delivery systems to target tissues like the liver with \u0026gt;90% uptake in hepatocytes in preclinical models; by 2025 it reports validated extrahepatic delivery to CNS and ocular tissues, advancing 2 clinical programs and securing \u0026gt;$300M in R\u0026amp;D funding to scale delivery tech; this moat enables highly specific RNAi medicines with lower off-target profiles versus small molecules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-Stage Pipeline Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam’s product strategy centers on late-stage assets like zilebesiran (siRNA for hypertension) and mivelsiran (siRNA for Alzheimer’s-linked targets), shifting focus from rare diseases to chronic, high-prevalence markets—hypertension affects ~1.3B adults globally and Alzheimer’s ~55M patients (2025 est.), expanding TAM materially.\u003c\/p\u003e\n\u003cp\u003ePhase 2\/3 and 2025 open-label data show blood-pressure reductions \u0026gt;15 mmHg for zilebesiran and target-engagement biomarker declines for mivelsiran, supporting potential to change cardiovascular and neuro care pathways and drive peak-year sales into multi-billion-dollar ranges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubcutaneous and Long-Acting Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpalnylam product mix shifts care from clinic infusions to patient-friendly subcutaneous injections boosting adherence and lowering administration costs quarterly biannual dosing for candidates like vutrisiran-era constructs targets fewer than annual doses. clinical studies show once-quarterly regimens raise persistence by versus daily oral drugs payer models project lower total cost of per patient-year in specialty populations.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubcutaneous, self-administered\u003c\/li\u003e\n\u003cli\u003eDosing: once-quarterly to biannual\u003c\/li\u003e\n\u003cli\u003e~20% higher adherence vs daily oral\u003c\/li\u003e\n\u003cli\u003e~15% lower payer cost per patient-year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Medicine and Diagnostic Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpalnylam pairs rnai therapeutics with diagnostic support to identify patients target genetic variants funding testing programs that cut delay reports partnerships expanding access over worldwide by this integration speeds time-to-treatment raises appropriate prescribing rates and boosts product value linking therapy confirmed biomarkers.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25,000+ patients in testing programs (2024)\u003c\/li\u003e\n\u003cli\u003eReduced diagnostic delay by ~40% in pilot networks\u003c\/li\u003e\n\u003cli\u003eHigher treatment yield: biomarker-confirmed prescribing up to 85%\u003c\/li\u003e\n\u003cli\u003eInvestment focus: genetic testing partnerships and payer engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam drives $3.6B 2025 revenue, Amvuttra \u0026amp; Leqvio boost adherence and cut costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam’s five marketed RNAi drugs plus Novartis-partnered Leqvio drove ~ $3.2B 2024 revenue and ~$3.6B 2025 guidance; Amvuttra led hATTR (65–70% share, ~$900–950M 2025 sales), Leqvio \u0026gt;$1.1B 2025. Proprietary GalNAc\/LNP delivery enables \u0026gt;90% hepatic uptake preclinically, extrahepatic programs advancing; dosing shifts to quarterly\/biannual, raising adherence ~20% and lowering payer cost ~15%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$3.2B \/ $3.6B guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmvuttra sales\u003c\/td\u003e\n\u003ctd\u003e$900–950M (2025 est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeqvio sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.1B (Novartis 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepatocyte uptake\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% preclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer cost drop\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Alnylam’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Alnylam’s 4P marketing insights into a concise, at-a-glance summary to streamline leadership briefings and cross-functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam maintains a direct commercial presence in over 30 countries across North America, Europe, and Japan, enabling control over pricing and distribution for its RNAi therapies.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 regional hubs in Boston, Zug, and Tokyo were matured to handle local regulatory filings and reimbursement negotiations, reducing launch lag by an estimated 4–6 months.\u003c\/p\u003e\n\u003cp\u003eThis footprint supports rapid scale-up: Alnylam increased commercial supply capacity 35% from 2023–2025 to meet demand and ensure consistent availability for rare-disease patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam uses strategic pharma alliances to access large markets, notably Novartis for Leqvio and Roche for zilebesiran, tapping their primary-care reach (Novartis’ cardiovascular network covers \u0026gt;100 countries; Roche’s commercial footprint reached $57B revenue in 2024). These deals let Alnylam focus R\u0026amp;D while leveraging partners’ sales scale—Novartis collaboration targets peak annual Leqvio sales \u0026gt;$5B; Roche tie accelerates outpatient rollout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Specialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam uses a select network of specialty pharmacies and distributors to manage high-cost, high-touch RNAi therapies, ensuring cold-chain handling and intensive patient monitoring for rare diseases.\u003c\/p\u003e\n\u003cp\u003eThis controlled distribution preserves product integrity and, as of 2025, helps track prescription fulfillment and patient persistence—Alnylam reported specialty channel adherence rates near 82% for key launches in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Hospital and Infusion Center Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam sells clinically administered RNAi therapies directly to academic medical centers and specialized infusion clinics, supporting delivery for severe genetic diseases like ATTR and hATTR where physician supervision is required.\u003c\/p\u003e\n\u003cp\u003eThe company runs training programs, cold-chain protocols, and reimbursement support; in 2025 Alnylam reported ~45% of U.S. in-market product units routed through hospital\/infusion channels, aiding 2024 product revenue of $1.9B.\u003c\/p\u003e\n\u003cp\u003eThe localized placement ensures access for complex infusions and improves adherence and safety through site certification and ongoing clinical education.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect hospital\/infusion focus\u003c\/li\u003e\n\u003cli\u003eSite training + cold-chain protocols\u003c\/li\u003e\n\u003cli\u003e45% U.S. channel share (2025)\u003c\/li\u003e\n\u003cli\u003eSupports $1.9B 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telemedicine Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam integrated digital platforms for remote monitoring and virtual consults to connect rural patients with RNAi therapy centers, supporting adherence and refill coordination; telemedicine usage rose 48% among its specialty clinic partners in 2024. By end-2025 these place strategies cut missed visits by 32% and helped sustain patient retention for chronic RNAi regimens.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e48% increase in telemedicine use (2024)\u003c\/li\u003e\n\u003cli\u003e32% reduction in missed visits (by 2025)\u003c\/li\u003e\n\u003cli\u003eImproved refill\/adherence coordination across 25+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam scales global launches, supply +35%, boosts adherence to 82% with telemed gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam runs direct commercial ops in 30+ countries, regional hubs (Boston, Zug, Tokyo) cut launch lag 4–6 months, and scaled supply +35% (2023–2025). Specialty pharmacies\/hospitals handle 45% U.S. units (2025); adherence ~82% (2024). Telemedicine use +48% (2024) reduced missed visits 32% by 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply growth\u003c\/td\u003e\n\u003ctd\u003e+35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hospital share\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence\u003c\/td\u003e\n\u003ctd\u003e82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelemed rise\u003c\/td\u003e\n\u003ctd\u003e+48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMissed visits ↓\u003c\/td\u003e\n\u003ctd\u003e32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAlnylam 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Alnylam 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750849753465,"sku":"alnylam-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alnylam-marketing-mix.png?v=1772226549","url":"https:\/\/growthsharematrix.com\/products\/alnylam-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}